Massachusetts General Hospital: Osteoporosis trials

The registry lists 15 Osteoporosis studies with Massachusetts General Hospital as lead sponsor. 1 are open to participants now and 10 have results posted.

Phase 2 7Phase 3 1Phase 4 5No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Combined Anabolic TherapyRecruitingNCT06558188Phase 4
• Bone Modeling Effects of Combined Anabolic/Antiresorptive AdministrationCompletedNCT04026256Phase 4Results posted
• Transdermal Estrogen in Older Premenopausal Women With Anorexia NervosaCompletedNCT02475265Phase 2Results posted
• Denosumab and Teriparatide Study (DATA-HD and DATA-EX)CompletedNCT02176382Phase 4Results posted
• Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone ResorptionCompletedNCT01750086Phase 4Results posted
• Testosterone and Alendronate in Hypogonadal MenTerminatedNCT01460654Phase 2Results posted
• IGF-1 and Bone Loss in Women With Anorexia NervosaCompletedNCT01406444Not applicableResults posted
• Denosumab, Teriparatide or Both for the Treatment of Postmenopausal OsteoporosisCompletedNCT00926380Phase 2Results posted
• The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia NervosaCompletedNCT00759772Phase 2Results posted
• Effect of Growth Hormone on Bone Metabolism in Anorexia NervosaCompletedNCT00283595Phase 2Results posted
• Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal WomenCompletedNCT00086619Phase 2Results posted
• Comparative Antiresorptive Efficacy Discontinuation of DenosumabActive, not recruitingNCT03623633Phase 4
• Bone Health in Youth With Type 1 DiabetesStatus unknownNCT02140424
• Effects of Parathyroid Hormone in Men With OsteoporosisCompletedNCT00000427Phase 3
• Alendronate and/or Parathyroid Hormone for OsteoporosisCompletedNCT00000400Phase 2